Please login to the form below

asset swap

This page shows the latest asset swap news and features for those working in and with pharma, biotech and healthcare.

GSK gained the two vaccines as part of a $20bn asset swap with Novartis in 2015, which was orchestrated by previous GSK CEO Sir Andrew Witty.

GSK pays $50m upfront to tap Immatics’ cell therapy platform

came on board, after all-but exiting the category a few years ago via an asset-swap deal with Novartis.
GSK licenses its tuberculosis vaccine to Gates MRI

asset-swap deal in 2014.
GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

The two travel vaccines were acquired as part of a $20bn asset swap with Novartis back in 2015.
Hudson named Brandicourt’s successor as Sanofi’s CEO

Olivier Brandicourt. Brandicourt presided over a restricting of Sanofi’s business, masterminding the exchange of its animal health business with Boehringer Ingelheim’s consumer health unit in a $25bn asset swap
GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

its cancer portfolio in 2015 as part of an asset-swap with Novartis.

More from news
Approximately 3 fully matching, plus 53 partially matching documents found.

Deal Watch February 2017

This transaction came as a result of the requirement that Sanofi had to divest certain assets from the Sanofi/ Boehringer Ingelheim asset swap of December 2015, in which Sanofi swapped its
The human perspective

Chief among these moves were the German company's exit from the generics business, via a $2.6bn deal with specialty firm Hikma, and its forthcoming asset swap with Sanofi. ... But looking at how a transaction such as the yet-to-be-completed asset swap
Deal Watch December 2015

Headline $m. Sanofi / Boehringer Ingelheim. Boehringer Ingelheim / Sanofi. Asset swap. ... 200. Sinclair IS (UK). Alliance. Acquisition - asset. Marketed dermatology range of products (Nov 2015).
Pharma deals in June 2015

Kythera's lead asset is Kybella, previously known as ATX-101, which is an FDA approved, proprietary injectable formulation of a synthetic version of deoxycholic acid for the reduction of submental ... This was the case following the $20bn asset swap deal
Allergan and taking a specialised approach

But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Bruno Strigini leaves Merck & Co for Novartis

The company has ambitions to expand in the therapy area, however, and recently acquired the bulk of GlaxoSmithKline's cancer portfolio in an asset swap deal valued at $16bn.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

No results were found

Add my company

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

The importance of accelerating clinical trial diversity: Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications: There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day: At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Email:
Password: